P-181 Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer (SOAP trial)

Abstract

Conventionally, the recommended duration of adjuvant chemotherapy had been 6 months. The recent combined analysis by the IDEA Collaboration for stage III colon cancer suggested that shortening the oxaliplatin-based adjuvant chemotherapy may be possible. Especially, in the IDEA low-risk stage III, 3 months of CAPOX was shown to be non-inferior to 6 months. S-1 and oxaliplatin treatment (SOX) + bevacizumab was shown to be non-inferior to FOLFOX + bevacizumab as first-line chemotherapy in metastatic colorectal cancer patients.